Get the Stockscreener App
5.17
42.42%
1.54
After Hours:
4.55
-0.62
-11.99%
Erasca Inc stock is traded at $5.17, with a volume of 41.05M.
It is up +42.42% in the last 24 hours and up +58.10% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$3.63
Open:
$3.73
24h Volume:
41.05M
Relative Volume:
15.31
Market Cap:
$1.47B
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-6.3049
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
+38.98%
1M Performance:
+58.10%
6M Performance:
+264.08%
1Y Performance:
+88.00%
1-Day Range:
$3.72
$6.49
1-Week Range:
$3.36
$6.49
52-Week Range:
$1.01
$6.49
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
5.17 | 1.03B | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Initiated | Stifel | Buy |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Erasca up 66% after WSJ report on AbbVie interest in Revolution Medicines - TipRanks
Erasca stock pulls back after 25% jump, Stifel cites competitor data By Investing.com - Investing.com Canada
Erasca stock pulls back after 25% jump, Stifel cites competitor data - Investing.com India
Erasca Inc stock hits 52-week high at $3.80 - Investing.com
Erasca Inc stock hits 52-week high at $3.80 By Investing.com - Investing.com Nigeria
Erasca initiated with an Overweight at Piper Sandler - TipRanks
Piper Sandler initiates Erasca stock with Overweight rating, $5 price target - Investing.com UK
Erasca price target raised to $2 from $1 at BofA - TipRanks
Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Fund Flows: How geopolitical tensions affect Erasca Inc stock2025 Market Sentiment & Real-Time Price Movement Reports - moha.gov.vn
Erasca (NASDAQ:ERAS) Trading Up 4.1% – Should You Buy? - Defense World
Aug Spikes: How Erasca Inc stock responds to policy changesJuly 2025 Drop Watch & Low Risk Growth Stock Ideas - moha.gov.vn
Erasca (ERAS) Valuation Check After S&P Biotechnology Select Industry Index Inclusion - Yahoo Finance
Did Index Inclusion and New RAS Patent Just Shift Erasca's (ERAS) Investment Narrative? - simplywall.st
Are Erasca Inc (ERAS) shares a good deal now? - uspostnews.com
Erasca, Inc.(NasdaqGS: ERAS) added to S&P Biotechnology Select Industry Index - marketscreener.com
Treasury Yields: Is Erasca Inc stock a buy on dipsWeekly Profit Summary & AI Powered Market Entry Strategies - moha.gov.vn
Why Erasca Inc. stock could be next big winnerWeekly Loss Report & Stock Portfolio Risk Management - Улправда
Will Erasca Inc. stock remain a Wall Street favoritePortfolio Update Summary & Risk Controlled Swing Trade Alerts - Улправда
Buyback Watch: Is Erasca Inc. stock a buy on dipsMarket Activity Summary & Daily Chart Pattern Signals - DonanımHaber
Aug Weekly: How Erasca Inc. stock responds to policy changesJuly 2025 Momentum & Free Long-Term Investment Growth Plans - DonanımHaber
Momentum Shift: Why Erasca Inc. stock could be next big winner2025 Geopolitical Influence & Comprehensive Market Scan Reports - Улправда
Erasca (ERAS) Valuation Check After ERAS-0015 Patent Extension and New Chief Scientific Officer Appointment - simplywall.st
Erasca Inc stock hits 52-week high at $3.68 - Investing.com India
Shareholder Erasca Foundation Files To Sell 8,333 Of Erasca Inc [ERAS] - TradingView — Track All Markets
Erasca Inc stock hits 52-week high at $3.68 By Investing.com - Investing.com Nigeria
Erasca (ERAS) Extends ERAS-0015 Patent to 2043 and Strengthens RAS Pipeline Momentum - simplywall.st
Discovering Opportunities: AirJoule Technologies Among 3 Promising Penny Stocks - simplywall.st
Erasca price target raised to $5 from $4 at Mizuho - MSN
Aug Breakouts: Is Erasca Inc stock a buy for dividend growthEarnings Growth Report & AI Optimized Trading Strategy Guides - moha.gov.vn
Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results - MSN
Platform Technologies Drive $211B Surge in Precision Cancer Treatment - marketscreener.com
Erasca, Inc Secures U.S. Patent Protection Through 2043 for ERAS-0015 - marketscreener.com
Mizuho Maintains Erasca (ERAS) Outperform Recommendation - Nasdaq
Check Out Erasca Inc (ERAS)’s Trade Data Rather Than the Analysts’ Views - Setenews
Mizuho raises Erasca stock price target to $5 on RAS space optimism - Investing.com Canada
Mizuho raises Erasca stock price target to $5 on RAS space optimism By Investing.com - Investing.com South Africa
Mizuho Raises Price Target on Erasca to $5 From $4, Keeps Outperform Rating - marketscreener.com
Erasca, Inc. (NASDAQ:ERAS) Given Average Rating of "Hold" by Analysts - MarketBeat
Affinity Asset Advisors LLC Grows Stock Holdings in Erasca, Inc. $ERAS - Defense World
Institutional Investors Show Growing Confidence in Erasca’s Prospects - AD HOC NEWS
Will Erasca Inc. stock outperform international peers2025 Top Gainers & Fast Gaining Stock Reports - Newser
Gitlab, Acadia Healthcare, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
Moving Averages: Why Erasca Inc. stock could be next big winnerInsider Buying & Momentum Based Trading Signals - moha.gov.vn
Unusually active option classes on open October 8th - MSN
Erasca to Present at the 8th Annual Evercore Healthcare Conference - The Manila Times
Adversity is less terrifying than hope: Erasca Inc (ERAS) - Setenews
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):